WallStSmart

PDD Holdings Inc. (PDD)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

PDD Holdings Inc. generates 13515% more annual revenue ($418.54B vs $3.07B). PDD leads profitability with a 24.4% profit margin vs 16.1%. PDD appears more attractively valued with a PEG of 1.03. PDD earns a higher WallStSmart Score of 77/100 (B+).

PDD

Strong Buy

77

out of 100

Grade: B+

Growth: 8.0Profit: 8.5Value: 10.0Quality: 8.5
Piotroski: 4/9Altman Z: 3.53

WST

Buy

55

out of 100

Grade: C-

Growth: 4.7Profit: 8.0Value: 4.7Quality: 7.3
Piotroski: 5/9Altman Z: 4.91
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

PDDUndervalued (+67.8%)

Margin of Safety

+67.8%

Fair Value

$332.33

Current Price

$102.61

$229.72 discount

UndervaluedFair: $332.33Overvalued
WSTSignificantly Overvalued (-256.8%)

Margin of Safety

-256.8%

Fair Value

$68.99

Current Price

$247.02

$178.03 premium

UndervaluedFair: $68.99Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

PDD6 strengths · Avg: 9.8/10
P/E RatioValuation
9.8x10/10

Attractively priced relative to earnings

Return on EquityProfitability
30.5%10/10

Every $100 of equity generates 31 in profit

Debt/EquityHealth
0.0310/10

Conservative balance sheet, low leverage

Free Cash FlowQuality
$45.66B10/10

Generating 45.7B in free cash flow

Altman Z-ScoreHealth
3.5310/10

Safe zone — low bankruptcy risk

Market CapQuality
$139.25B9/10

Large-cap with strong market position

WST2 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
4.9110/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Areas to Watch

PDD0 concerns · Avg: 0/10

No major concerns identified

WST3 concerns · Avg: 3.3/10
P/E RatioValuation
36.1x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
2.1%4/10

2.1% earnings growth

PEG RatioValuation
2.892/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : PDD

The strongest argument for PDD centers on P/E Ratio, Return on Equity, Debt/Equity. Profitability is solid with margins at 24.4% and operating margin at 23.1%. PEG of 1.03 suggests the stock is reasonably priced for its growth.

Bull Case : WST

The strongest argument for WST centers on Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.1% and operating margin at 21.6%.

Bear Case : PDD

No major red flags identified for PDD, but monitor valuation.

Bear Case : WST

The primary concerns for WST are P/E Ratio, EPS Growth, PEG Ratio.

Key Dynamics to Monitor

WST carries more volatility with a beta of 1.18 — expect wider price swings.

PDD is growing revenue faster at 9.0% — sustainability is the question.

PDD generates stronger free cash flow (45.7B), providing more financial flexibility.

Monitor INTERNET RETAIL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

PDD scores higher overall (77/100 vs 55/100), backed by strong 24.4% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

PDD Holdings Inc.

CONSUMER CYCLICAL · INTERNET RETAIL · China

Pinduoduo Inc., operates an electronic commerce platform in the People's Republic of China. The company is headquartered in Shanghai, the People's Republic of China.

Visit Website →

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?